MicroPort CardioFlow Medtech Corporation announced that, on December 28, 2021, the Company completed the registration application of CE Mark for VitaFlow Liberty transcatheter aortic valve implantation system, second generation transcatheter aortic heart valve TM implantation product. VitaFlow Liberty is the only TAVI product developed in China that had conducted clinical trial in Europe. VitaFlow Liberty has received its registration approval from the National Medical Products Administration of the People's Republic of China on August 30, 2021.